Exosomes From Mesenchymal Stem Cells for Treatment of Malignant Mesothelioma
Abstract
Over the past decade, trafficking of extracellular vesicles including exosomes has emerged as a mechanism of cell-cell communication and plays an important role in tumorigenesis and formation of the tumor microenvironment. We hypothesize that different antitumor activities of CD90low and CD90high mesenchymal stem cells (MSCs) are applicable to treatment of malignant mesothelioma (MM) and that the effects of MSCs are related to their secreted exosomes. Exosome-based nanometric vehicles have a number of advantages: they are non-toxic, non-immunogenic, and can be engineered to have robust delivery capacity and targeting specificity. Results from prior study periods demonstrated greater in vivo antitumor activity of CD90low ADSCs compared to CD90high ADSCs. During this study period we have optimized conditions for reproducible differentiation and culture of CD90high and CD90low ADSCs, and have established standardized protocols for the isolation of exosomes derived from these cells. Exosomes from both cell types have been prepared in sufficient quantities to support a study designed to test the anti-tumor activity of these ADSC-derived exosomes in a mouse model of MM.
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 01, 2023
- Accession Number
- AD1226545
Entities
People
- Mark C. Poznansky
- Sonia Mukherjee
Organizations
- Massachusetts General Hospital